Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART19.1 in refractory systemic lupus erythematosus
2023-507654-33-00Phase 2Authorised
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Aug 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of zorpocabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by Miltenyi Biomedicine GmbH. Planned start Aug 2024; status: authorised.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-507654-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507654-33-00.